Rankings
▼
Calendar
CHRS FY 2024 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena
CHRS
Coherus Oncology, Inc.
$226M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$267M
+3.8% YoY
Gross Profit
$149M
56.0% margin
Operating Income
-$112M
-41.8% margin
Net Income
$29M
10.7% margin
EPS (Diluted)
$0.25
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$20M
Stock-Based Comp.
$28M
Balance Sheet
Total Assets
$449M
Total Liabilities
$581M
Stockholders' Equity
-$132M
Cash & Equivalents
$126M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$267M
$257M
+3.8%
Gross Profit
$149M
$98M
+52.1%
Operating Income
-$112M
-$203M
+45.0%
Net Income
$29M
-$238M
+112.0%
← Q4 2023
All Quarters
Q1 2024 →